Contrast nephropathy: An evidence-based approach to prevention

American Journal of Cardiovascular Drugs

Volumn 3, Issue 6, 2003, Pages 395-405

  Kandzari, David E ^a   Rebeiz, Abdallah G ^a   Wang, Andrew ^a   Sketch Jr , Michael H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ACETYLCYSTEINE; AMINOPHYLLINE; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; CREATININE; DIATRIZOATE; DIURETIC AGENT; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; FUROSEMIDE; INFUSION FLUID; IODIXANOL; IOHEXOL; IOXAGLIC ACID; MANNITOL; NIFEDIPINE; NITRENDIPINE; PLACEBO; PROSTAGLANDIN E1;

ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DATA ANALYSIS; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; HYDRATION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; MEDICAL LITERATURE; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RADIOGRAPHY; REVIEW; RISK FACTOR;

ANIMALS; CONTRAST MEDIA; HUMANS; KIDNEY FAILURE, ACUTE; RISK FACTORS;

EID: 0346895373     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303060-00003     Document Type: Review

References (73)

1. Berns AS. Nephrotoxicity of contrast media. Kidney Int 1989; 36: 730-40
2. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75
3. Deray G, Jacobs C. Radiocontrast nephrotoxicity: a review. Invest Radiol 1995; 30: 221-5
4. Hou S, Bushinsky D, Wish J, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74: 243-8
5. Iakovou I, Dangas G, Lansky AJ, et al. Predictors of contrast induced nephropathy after percutaneous coronary intervention in patients with and without chronic renal failure [abstract]. J Am Coll Cardiol 2002, 39; 56A
6. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995; 47: 254-61
7. Mason RA, Arbeit LA, Giron F. Renal dysfunction after arteriography. JAMA 1985; 253: 1001-4
8. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age and older: a prospective study. Arch Intern Med 1990; 150: 1237-42
9. D'Elia JA, Gleason R, Alday M, et al. Nephrotoxicity from angiography: a prospective study. Am J Med 1982; 72: 719-24
10. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-64
11. Brezis M, Rosen S. Hypoxia of the renal medulla: its implications for disease. N Engl J Med 1995; 332: 647-55
12. Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5: 125-7
13. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990; 258: F115-20
14. Baliga R, Ueda N, Walker PD, et al. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997; 29: 465-77
15. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992; 41: 1008-15
16. Pflueger A, Larson TS, Nath KA, et al. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc 2000; 75: 1275-83
17. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the PRINCE Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999; 33: 403-11
18. Deray G. Nephrotoxicity of contrast media. Nephrol Dial Transplant 1999; 14: 2602-6
19. 1: a randomized, double-blind, placebo-controlled study. Am J Ther 2001; 8: 155-62
20. Margulies KB, Hildebrand FL, Heublein DM, et al. Radiocontrast increases plasma and urinary endothelin. J Am Soc Nephrol 1991; 2: 1041-5
21. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelial receptor antagonism. Kidney Int 2000; 57: 1675-80
22. Tommaso CL. Contrast-induced nephrotoxicity in patients undergoing cardiac catheterization. Cathet Cardiovasc Diagn 1994; 31: 316-21
23. Janzen EG. Spin trapping of oxygen radicals. Methods Enzymol 1982; 105: 188-203
24. Brinker JA. No CAN? Cathet Cardiovasc Interv 2001; 52: 417-9
25. Fang LS, Sirota RA, Ebert TH, et al. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med 1980; 140: 531-3
26. Kini A, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist in preventions of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001; 2: S19-25
27. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure oil mortality: a cohort analysis. JAMA 1996; 275: 1489-94
28. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542-8
29. Tublin ME, Murphy ME, Tessler FN. Current concepts in contrast media-induced nephropathy. AJR Am J Roentgenol 1998; 171: 933-9
30. Batchelor WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions in 7,472 octogenarians. J Am Coll Cardiol 2000; 36: 723-30
31. Taliercio CP, Vliestra RE, Fisher LD, et al. Risks for renal dysfunction with dysfunction with cardiac angiography. Ann Intern Med 1986; 110: 119-24
32. Manske CL, Sprafka JM, Strony JT, et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-20
33. Byrd L, Sherman RL. Radiocontrast-induced acute renal failure: a clinical and pathophysiologic review. Medicine 1979; 58: 270-9
34. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320: 149-53
35. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171-8
36. Davidson CJ, Laskey WK, Hermiller JB, et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000; 10: 2172-7
37. Solomon RC, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-20
38. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413-5
39. Neumayer HH, Junge CW, Kufner A, et al. Prevention of radiocontrast media induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989; 4: 1030-6
40. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995; 15: 59-65
41. Russo D, Testa A, Volpe LD, et al. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 1990; 55: 254-77
42. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45: 259-65
43. Hans SS, Hans BA, Dhillon R, et al. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 1998; 64: 432-6
44. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999; 34: 1682-8
45. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999; 83: 260-3
46. Tumlin JA, Wang A, Murray PT, et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143: 894-903
47. Miller WL, Redfield MM, Burnett Jr JC. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest 1989; 83: 317-20
48. Cantley LG, Spokes K, Clark B, et al. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993; 444: 1217-23
49. Brooks DP, DePalma PD. Blockade of radiocontrast-induced nephrotoxicity by the endothelin receptor antagonist, SB 209670. Nephron 1996; 72: 629-36
50. Weisberg LS, Kurnik PB, Kurnik BRC. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren Fail 1993; 15: 61-8
51. Kien ND, Moore PG, Jaffe RS. Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthezed dogs. Anesth Analg 1992; 74: 72-8
52. Bakris GL, Lass NA, Glock DA. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int 1999; 56: 206-10
53. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 200; 31: 743-55
54. Tumlin JA, Dunbar LM, Oparil S, et al. Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter, randomized trial. Acad Emerg Med 2000; 7: 653-62
55. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27: 1832-7
56. Mathur VS, Cary R, O'Connell D. Renal and systemic effects of very low-dose fenoldopam in normotensive subjects [abstract]. Anesth Analg 1999; 88: SCA 85
57. Allison N, Dubb J, Ziemniak J, et al. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 1987; 41: 282-8
58. Madyoon H, Croushore L, Weaver D, et al. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Cathet Cardiovasc Interv 2001; 53: 341-5
59. Shammas NW, Kapalis MJ, Harris M, et al. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol 2001; 13: 738-40
60. Kurnik BRC, Allgren RL, Genter FC, et al. Prospective study if atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31: 674-80
61. Stone GW, Tumlin JA, Madyoon H, et al. Design and rationale of CONTRAST: a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. Rev Cardiovasc Med 2001; 2: S31-6
62. Parvez Z, Rahman MA, Moncada R. Contrast media-induced lipid peroxidation in the rat kidney. Invest Radiol 1989; 24: 697-702
63. DiMari J, Megyesi J, Udvarhelyi N, et al. N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol 1997; 272: F292-8
64. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-4
65. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to Prevent Angiography-related Renal Tissue Injury (the APART trial). Am J Cardiol 2002; 89: 356-8
66. Adamian MG, Moussa I, Mehran R, et al. The role of mucomyst administration prior to percutaneous interventions on renal function in patients with chronic renal failure [abstract]. J Am Coll Cardiol 2002; 39: 1A
67. Mouhayar EN, Tadros G, Akin AO, et al. Prevention of contrast-induced renal dysfunction with acetylcysteine in patients undergoing coronary angiography [abstract]. J Am Coll Cardiol 2002; 39: 1A
68. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40: 298-303
69. Caputo C, Dokko JH, Durham JH, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy following coronary angiography [abstract]. Am J Kidney Dis 2002; 39: A1014
70. Oliveira D. Prophylaxis against contrast-induced nephropathy. Lancet 1999; 353: 1638-9
71. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-36
72. Taylor AJ, Hotchkiss D, Morse RW, et al. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient versus outpatient hydration protocols for cardiac catheterization in mild to moderate renal dysfunction. Chest 1998; 114: 1570-4
73. Marenzi G, Lauri G, Assanelli A, et al. Prevention of renal function worsening after percutaneous coronary interventions by hemofiltration in patients at high risk for contrast nephropathy [abstract]. J Am Coll Cardiol 2002; 39: 1A